[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.130.145. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
January 13, 1997

Is the Course of Neurocysticercosis Modified by Treatment With Anthelmintic Agents?

Author Affiliations

Guayaquil, Ecuador

Arch Intern Med. 1997;157(1):128-129. doi:10.1001/archinte.1997.00440220134017
Abstract

It is with great surprise that I read the article on anticysticercal drug therapy by Carpio et al.1 In that study, anticysticercal drugs were not better than symptomatic therapy for the resolution of parenchymal brain cysticerci and did not modify the clinical course of the disease. These results differ from those reported in most studies about praziquantel or albendazole therapy for parenchymal neurocysticercosis (NC)2-10 and did not match with those previously reported by the same authors in the same population of patients with NC. In 1988, Carpio et al11 described 20 patients with parenchymal NC in whom albendazole was highly effective and caused a 84% reduction in the number of brain cysts. Because albendazole has been used to treat human NC since 1986,3 it must be assumed that those 20 patients had to be included in their 1995 study, because, according to the authors, "Between July

First Page Preview View Large
First page PDF preview
First page PDF preview
×